Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Spero Therapeutics Inc (SPRO)

Spero Therapeutics Inc (SPRO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 52,070
  • Shares Outstanding, K 54,518
  • Annual Sales, $ 103,780 K
  • Annual Income, $ 22,810 K
  • EBIT $ -1 M
  • EBITDA $ -1 M
  • 60-Month Beta 0.59
  • Price/Sales 0.52
  • Price/Cash Flow 1.93
  • Price/Book 0.82
  • Price/Earnings ttm 14.26
  • Earnings Per Share ttm 0.07
  • Most Recent Earnings $-0.32 on 11/14/24
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 244.03% ( -126.57%)
  • Historical Volatility 36.26%
  • IV Percentile 64%
  • IV Rank 30.35%
  • IV High 765.88% on 12/10/24
  • IV Low 16.63% on 02/27/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 6
  • Volume Avg (30-Day) 10
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 1,939
  • Open Int (30-Day) 1,882

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.31
  • Number of Estimates 2
  • High Estimate -0.27
  • Low Estimate -0.35
  • Prior Year 0.96
  • Growth Rate Est. (year over year) -132.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9501 +0.53%
on 12/20/24
1.2300 -22.35%
on 11/22/24
-0.2449 (-20.41%)
since 11/20/24
3-Month
0.9501 +0.53%
on 12/20/24
1.3899 -31.28%
on 09/30/24
-0.3749 (-28.19%)
since 09/20/24
52-Week
0.9501 +0.53%
on 12/20/24
1.8900 -49.47%
on 03/14/24
-0.3949 (-29.25%)
since 12/20/23

Most Recent Stories

More News
RARE Submits BLA to the FDA for Sanfilippo Syndrome Gene Therapy

Ultragenyx Pharmaceutical RARE announced that it has submitted a biologics license application (BLA) to the FDA for its UX111 (ABO-102) AAV gene therapy as a treatment for patients with Sanfilippo syndrome...

CTMX : 1.0900 (-0.91%)
RARE : 44.22 (+1.73%)
CSTL : 27.53 (+1.62%)
SPRO : 0.9551 (-4.30%)
Roche's Prasinezumab Misses Goal in Parkinson's Disease Study

Roche RHHBY announced data from the phase IIb PADOVA study which evaluated its investigational monoclonal antibody, prasinezumab, for treating people with early-stage Parkinson’s disease.The double-blind...

CSTL : 27.53 (+1.62%)
PRTA : 15.22 (-4.93%)
RHHBY : 34.5000 (+0.76%)
SPRO : 0.9551 (-4.30%)
KRYS Reports Upbeat Initial Data From Lung Cancer Study of KB707

Krystal Biotech KRYS announced encouraging initial clinical data from an early to mid-stage study of its investigational immunotherapy candidate, KB707, to treat patients with solid tumors of the lung.The...

KRYS : 164.83 (+2.49%)
CTMX : 1.0900 (-0.91%)
CSTL : 27.53 (+1.62%)
SPRO : 0.9551 (-4.30%)
EWTX Stock Rises on Upbeat Data From Rare Muscular Disorder Study

Shares of Edgewise Therapeutics EWTX were up more than 18% on Monday after it announced positive results from the mid-stage CANYON study on its lead pipeline drug, sevasemten, in patients with a rare genetic...

CTMX : 1.0900 (-0.91%)
EWTX : 30.78 (-0.06%)
CSTL : 27.53 (+1.62%)
SPRO : 0.9551 (-4.30%)
EDIT Stock Falls on Decision to End Reni-Cel Studies, Cut Workforce

Shares of Editas Medicine EDIT plunged 23.8% on Dec. 13 after it announced a strategic decision to end the development of its lead gene editing therapy, reni-cel, following the failure of an extensive...

CTMX : 1.0900 (-0.91%)
CSTL : 27.53 (+1.62%)
EDIT : 1.3100 (-2.24%)
SPRO : 0.9551 (-4.30%)
KRYS Stock Down on Initial Clinical Updates on KB407 & KB408

Krystal Biotech, Inc. KRYS announced initial clinical data updates on its two inhaled genetic medicine pipeline candidates, KB407 and KB408, which are being developed in early-stage studies for treating...

KRYS : 164.83 (+2.49%)
CTMX : 1.0900 (-0.91%)
CSTL : 27.53 (+1.62%)
SPRO : 0.9551 (-4.30%)
Here's Why Q32 Bio Stock Hit a New Record Low on Wednesday

Shares of Q32 Bio QTTB lost nearly 77% yesterday after it reported mixed results from two separate phase IIa studies evaluating its investigational drug bempikibart  one in atopic dermatitis (AD or eczema)...

CTMX : 1.0900 (-0.91%)
CSTL : 27.53 (+1.62%)
QTTB : 3.59 (+7.49%)
SPRO : 0.9551 (-4.30%)
CORT's Dazucorilant Fails to Meet Goal in Neurologic Disorder Study

Corcept Therapeutics Incorporated CORT announced data from the phase II DAZALS study evaluating its selective cortisol modulator, dazucorilant, for treating patients with amyotrophic lateral sclerosis...

CORT : 51.40 (+0.49%)
IMCR : 28.33 (-0.33%)
CSTL : 27.53 (+1.62%)
SPRO : 0.9551 (-4.30%)
Beam Therapeutics Appoints Sravan Emany as New CFO, Shares Up

Shares of Beam Therapeutics Inc. BEAM were up 5.5% on Dec. 6 after the company announced that it has appointed Sravan K. Emany as its new chief financial officer (CFO).He will assume his new role on Dec....

BEAM : 29.01 (+8.04%)
IMCR : 28.33 (-0.33%)
CSTL : 27.53 (+1.62%)
SPRO : 0.9551 (-4.30%)
AFMD Stock Down Despite FDA's RMAT Status for Lymphoma Therapy

Affimed N.V. AFMD announced that the FDA has granted the Regenerative Medicine Advanced Therapy (RMAT) designation to its pipeline candidate, acimtamig (AFM13).The regulatory body granted the RMAT designation...

AFMD : 1.1900 (+0.85%)
CSTL : 27.53 (+1.62%)
SPRO : 0.9551 (-4.30%)
ARTV : 11.11 (+11.10%)

Business Summary

Spero Therapeutics Inc. is a multi-asset, clinical-stage biopharmaceutical company. It focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections. Spero Therapeutics Inc. is based in CAMBRIDGE, United States.

See More

Key Turning Points

3rd Resistance Point 1.0199
2nd Resistance Point 1.0050
1st Resistance Point 0.9800
Last Price 0.9551
1st Support Level 0.9401
2nd Support Level 0.9252
3rd Support Level 0.9002

See More

52-Week High 1.8900
Fibonacci 61.8% 1.5310
Fibonacci 50% 1.4201
Fibonacci 38.2% 1.3091
Last Price 0.9551
52-Week Low 0.9501

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar